- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05424120
Thoracentesis QI Study
November 3, 2023 updated by: University of Minnesota
Thoracentesis Quality Improvement (QI) Study
Researchers will compare 3 standard of care methods of pleural fluid drainage during therapeutic thoracentesis.
Patients are randomized to manual aspiration, vacuum bottle drainage or wall suction methods.
Primary outcome is procedural time with secondary outcomes of pain and dyspnea scores.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
102
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Katie Capp, MD
- Phone Number: 717-309-9829
- Email: capp0044@umn.edu
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age >18
- Evidence of pleural effusion on imaging
- Clinical indication for thoracentesis
Exclusion Criteria:
- Age <18
- Standard contraindication for thoracentesis procedure
- Patients on positive pressure ventilation
- Patients who have opted out of research in EPIC
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Manual aspiration
pleural fluid is drained using a standard thoracentesis kit and via a syringe and three-way stopcock
|
One option from standard of care
|
Active Comparator: Wall suction
pleural fluid is drained using a standard thoracentesis kit and by attaching tubing to wall suctioning set at -50 mmHg continuously
|
One option from standard of care
|
Active Comparator: Vacuum bottle drainage
pleural fluid is drained using a standard thoracentesis kit and tubing that attaches to a glass vacuum container
|
One option from standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedural time to 500mL
Time Frame: Through study completion, an average of 24 hours
|
Time to pleural fluid drainage from initiation of therapeutic drainage to 500mL
|
Through study completion, an average of 24 hours
|
Procedural time to 750mL
Time Frame: Through study completion, an average of 24 hours
|
Time to pleural fluid drainage from initiation of therapeutic drainage to 750mL
|
Through study completion, an average of 24 hours
|
Procedural time to 1L
Time Frame: Through study completion, an average of 24 hours
|
Time to pleural fluid drainage from initiation of therapeutic drainage to 1L
|
Through study completion, an average of 24 hours
|
Pain and dyspnea scores- Baseline
Time Frame: Immediately prior to starting the thoracentesis
|
Patients will be asked to indicate their pain and dyspnea level verbally using the Modified Borg Scale for Dyspnea and Numerical Ratings Scale (0-10, with 10 being highest level of pain)
|
Immediately prior to starting the thoracentesis
|
Pain and dyspnea scores- Cath
Time Frame: Through study completion, an average of 24 hours
|
Patients will be asked to indicate their pain and dyspnea level verbally using the Modified Borg Scale for Dyspnea and Numerical Ratings Scale (0-10, with 10 being highest level of pain)
|
Through study completion, an average of 24 hours
|
Pain and dyspnea scores- Post-fluid
Time Frame: Through study completion, an average of 24 hours
|
Patients will be asked to indicate their pain and dyspnea level verbally using the Modified Borg Scale for Dyspnea and Numerical Ratings Scale (0-10, with 10 being highest level of pain)
|
Through study completion, an average of 24 hours
|
Pain and dyspnea scores- Post-cath
Time Frame: Immediately after removing the thoracentesis catheter
|
Patients will be asked to indicate their pain and dyspnea level verbally using the Modified Borg Scale for Dyspnea and Numerical Ratings Scale (0-10, with 10 being highest level of pain)
|
Immediately after removing the thoracentesis catheter
|
Pain and dyspnea scores- 5m post
Time Frame: 5 minutes post-procedure
|
Patients will be asked to indicate their pain and dyspnea level verbally using the Modified Borg Scale for Dyspnea and Numerical Ratings Scale (0-10, with 10 being highest level of pain)
|
5 minutes post-procedure
|
Pain and dyspnea scores- 24h post
Time Frame: 24 hours post-procedure
|
Patients will be asked to indicate their pain and dyspnea level verbally using the Modified Borg Scale for Dyspnea and Numerical Ratings Scale (0-10, with 10 being highest level of pain)
|
24 hours post-procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Roy Cho, MD, University of Minnesota
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 18, 2022
Primary Completion (Actual)
June 30, 2023
Study Completion (Actual)
June 30, 2023
Study Registration Dates
First Submitted
April 25, 2022
First Submitted That Met QC Criteria
June 14, 2022
First Posted (Actual)
June 21, 2022
Study Record Updates
Last Update Posted (Actual)
November 7, 2023
Last Update Submitted That Met QC Criteria
November 3, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PACCS-2021-30297
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pleural Effusion
-
Naestved HospitalTerminatedMalignant Pleural Effusion | Exudative Pleural EffusionDenmark
-
Oregon Health and Science UniversityThe Gerber FoundationCompletedChylous Pleural Effusion Following Cardiothoracic SurgeryUnited States
-
Sheng HuWuhan Binhui Biotechnology Co., Ltd.RecruitingMalignant Pleural Effusion | Malignant Peritoneal EffusionChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPleural NeoplasmUnited States
-
Clover Biopharmaceuticals AUS Pty LtdCompletedMalignant Pleural EffusionsAustralia
-
JemincareZhejiang Hangyu Pharmaceutical Co., LtdRecruitingMalignant Pleural EffusionChina
-
National University of Ireland, Galway, IrelandRecruitingMalignant Pleural EffusionIreland
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Not yet recruiting
-
Washington University School of MedicineMerit Medical Systems, Inc.CompletedMalignant Pleural EffusionUnited States
-
Duke UniversityTerminated
Clinical Trials on Manual aspiration
-
The Young Investigator Group of Cardiovascular...SuspendedCoronary Artery Disease | ST Elevation Myocardial Infarction | Percutaneous Coronary InterventionEgypt
-
Population Health Research InstituteUppsala University; University Medical Center Groningen; Region Örebro County; University...CompletedMyocardial Infarction | Acute Coronary Syndromes
-
IsalaCompletedPneumothoraxNetherlands
-
Çankırı Karatekin UniversityThe Scientific and Technological Research Council of TurkeyCompleted
-
Careggi HospitalCardiovascular Research Foundation, New YorkCompletedST-segment Elevation Myocardial Infarction | ThrombusItaly
-
Vidacare CorporationCompletedBone Marrow Aspiration and Biopsy Specimen CollectionUnited States
-
Population Health Research InstituteCompletedST Elevation Myocardial Infarction | Acute Coronary Syndrome | Percutaneous Coronary InterventionCanada, United States, Korea, Republic of, United Kingdom, Spain, New Zealand, France, Greece, Austria, Netherlands, Germany, Finland, Serbia, Czech Republic, Australia, Hungary, Brazil, Belgium, China, Macedonia, The Former Yugoslav...
-
University of LeipzigCompletedMyocardial InfarctionGermany
-
Washington University School of MedicineCompletedAbortion in First TrimesterUnited States
-
Vidacare CorporationCompletedBone Marrow Biopsy ProceduresUnited States, Spain